Are prostate-specific antigen changes valid surrogates for survival in hormone-refractory prostate cancer? A meta-analysis is needed! - In reply

被引：0
作者：
Armstrong, Andrew J. [1 ]
Garrett-Mayer, Elizabeth [2 ]
Eisenberger, Mario [2 ]
Tannock, Ian [3 ,4 ]
de Wit, Ronald [5 ]
机构：
[1] Duke Comprehens Canc Ctr, Durham, NC 27710 USA
[2] Johns Hopkins Sch Med, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA
[3] Princess Margaret Hosp, Dept Med Oncol, Toronto, ON M4X 1K9, Canada
[4] Univ Toronto, Toronto, ON, Canada
[5] Erasmus Univ, Med Ctr, Rotterdam Canc Inst, Dept Med Oncol, Rotterdam, Netherlands
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2007年 / 25卷 / 35期
关键词：
D O I：
10.1200/JCO.2007.14.5383
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：5674 / 5674
页数：1
相关论文
共 6 条
  • [1] Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer
    Armstrong, Andrew J.
    Garrett-Mayer, Elizabeth
    Yang, Yi-Chun Ou
    Carducci, Michael A.
    Tannock, Ian
    de Wit, Ronald
    Eisenberger, Mario
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (25) : 3965 - 3970
  • [2] Criteria for the validation of surrogate endpoints in randomized experiments
    Buyse, M
    Molenberghs, G
    [J]. BIOMETRICS, 1998, 54 (03) : 1014 - 1029
  • [3] COLLETTE L, J CLIN ONCOL, P25
  • [4] Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16
    Petrylak, DP
    Ankerst, DP
    Jiang, CS
    Tangen, CM
    Hussain, MHA
    Lara, PN
    Jones, JA
    Taplin, ME
    Burch, PA
    Kohli, M
    Benson, MC
    Small, EJ
    Raghavan, D
    Crawford, ED
    [J]. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2006, 98 (08) : 516 - 521
  • [5] Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: A Canadian randomized trial with palliative end points
    Tannock, IF
    Osoba, D
    Stockler, MR
    Ernst, DS
    Neville, AJ
    Moore, MJ
    Armitage, GR
    Wilson, JJ
    Venner, PM
    Coppin, CML
    Murphy, KC
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (06) : 1756 - 1764
  • [6] Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer
    Tannock, IF
    de Wit, R
    Berry, WR
    Horti, J
    Pluzanska, A
    Chi, KN
    Oudard, S
    Theodore, C
    James, ND
    Turesson, I
    Rosenthal, MA
    Eisenberger, MA
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (15) : 1502 - 1512
1